Key recommendations from the 2025 ADA Standards of Care in Diabetes guidelines
| Section | Key recommendations (2025) |
|---|---|
| Diagnosis | Consider antibody-based screening for presymptomatic type 1 diabetes in individuals with a family history of the disease |
| Pharmacological advances | GLP-1 RA or dual GIP-GLP-1 RA are recommended for their multifaceted benefits in diabetes management |
| Dietary guidance | Importance of adequate water consumption highlightedRecommend high-quality, sustainable eating patterns such as the plant-based dietReplace sugar with non-nutritive sweeteners in moderation and short term to aid caloric restriction |
| Digital technology | Strongly recommend CGM for individuals with T2DM on non-insulin regimens as well as those on insulin |
ADA: American Diabetes Association; GLP-1 RA: glucagon-like peptide-1 receptor agonist; GIP: glucose-dependent insulinotropic polypeptide; CGM: continuous glucose monitoring; T2DM: type 2 diabetes mellitus